摘要
目的探究特利加压素联合前列地尔治疗肝硬化难治性腹水的疗效。方法以2014年2月~2016年2月本院收治的50例肝硬化难治性腹水患者作为研究对象,根据随机分为两组,每组各25例。对照组在常规治疗基础上予以前列地尔治疗,观察组在常规治疗的基础上予以特利加压素联合前列地尔进行治疗,观察两组患者治疗后的临床疗效、门静脉内径、脾静脉内径变化和基本体征情况。结果观察组患者的治疗总有效率、门静脉内径、脾静脉内径变化和基本体征均优于对照组,差异显著(P<005)。结论特利加压素联合前列地尔治疗肝硬化难治性腹水效果显著,有利于提高患者生存质量。
Objective To explore the curative effect of terlipressin combined with alprostadil in the treatment of liver cirrhosis with refractory ascites Methods50patients with refractory ascites due to cirrhosis in our hospital from February2014to February2016were selected as the research object They were randomly divided into two groups with25cases in each group The control group received alprostadil treatment,and the observation group treated with terlipressin combined with Alprostadil The clinical effect of portal vein,splenic vein and the change of basic signs of two groups of patients after treatment were investigated Results The total effective rate,the diameter of portal vein,the internal diameter of splenic vein and the basic signs in the observation group were significantly better than those in the control group(P<005)Conclusion The effect of terlipressin combined with alprostadil in the treatment of liver cirrhosis with refractory ascites was remarkable,and it is beneficial to improve the quality of life of patients
作者
王培培
WANG Pei-pei(Department of Internal Medicine,Shangqiu Infectious Disease Hospital,Shangqiu, Henan, 476100,China)
出处
《临床研究》
2017年第12期31-32,共2页
Clinical Research
关键词
特利加压素
前列地尔
肝硬化难治性腹水
疗效
terlipressin
alprostadil
refractory cirrhosis ascites
curative effect
